JZJianghua Zheng

Jianghua Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianghua Zheng has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Feasibility of robotic-assisted surgery for nutcracker syndrome: a systematic review and single-arm meta-analysis

    by Yue-Long Zhong, Shi-Guang Li, Zhu-Jun Yue, Zhi-Tao He, Qiang Tan, Jing-Quan Chen, Jiang-Hua Zheng

  • Open Access

    The real-world safety evaluation of the selective NaV1.8 inhibitor suzetrigine: disproportionality analysis and flexible empirical bayes signals from FAERS with external triangulation

    by Kun Lai, Lan Luo, Fuzhao Zhang, Eugenie Sin Sing Tan, Anand Gaurav, Jianghua Zheng, Chung Keat Tan

    Background: Suzetrigine (Journavx; VX-548), the first selective NaV1.8 voltage-gated sodium channel inhibitor approved by the FDA on 30 January 2025, represents a novel non-opioid option for moderate-to-severe acute pain. Given its recent market entry and unique peripheral mechanism, comprehensive post-marketing safety surveillance is essential. Objective: This study aimed to identify and characterize adverse event signals associated with suzetrigine in the FDA Adverse Event Reporting System (FAERS) using advanced disproportionality and comparator-referenced empirical Bayes (EB) methods, with external triangulation against published literature and WHO VigiBase data. Methods: We analyzed FAERS reports through the first 8 months post-approval. Disproportionality metrics (ROR, PRR, IC) were supplemented by a comparator-referenced EB profiling approach that incorporated suzetrigine, acetaminophen, ibuprofen, and background “other drugs,” generating 3,000 posterior draws per preferred term (PT). Signals with EB q05 > 2 and no comparator overlap were classified as suzetrigine-unique. High-priority PTs were triangulated with Phase II/III trial data, systematic reviews, case reports, and VigiBase report counts (February 2026). Results: Of 19 prioritized PTs, 14 were suzetrigine-unique. Dominant clusters included sensory disturbances (paresthesia, burning sensation, skin burning sensation, hypoaesthesia; EB q05 11.43–31.16), musculoskeletal events (muscle spasms EB q05 31.15), and cutaneous reactions (pruritus, rash). These signals were mechanistically consistent with peripheral NaV1.8 blockade of nociceptors and pruriceptors. Literature and VigiBase data corroborated neurological/sensory and musculoskeletal signals; psychiatric signals (euphoric mood, abnormal dreams) lacked external support and were deprioritized. Conclusion: This real-world pharmacovigilance analysis identifies a distinct safety signature for suzetrigine, with neurological and sensory disturbances (e.g., paresthesia, burning sensation, skin burning sensation, hypoaesthesia) emerging as prominent signals not fully characterized in pre-approval trials, whereas musculoskeletal and cutaneous events largely align with labeled reactions. These hypothesis-generating findings highlight the need for focused post-marketing surveillance on neurological/sensory preferred terms through prospective cohort studies and Phase IV trials to quantify incidence, identify risk factors, and optimize risk-minimization strategies for this promising non-opioid analgesic.


  • Open Access

    The Naples prognostic score as a new predictive index of severe abdominal aortic calcification: a population-based study

    by Qiang Tan, Jian Zhang, Yanrong Peng, Rui Yang, Yanbin Zhu, Xi Yong, Hongshun Yin, Jianghua Zheng

    Purpose: Abdominal aortic calcification (AAC) is related to inflammation and nutritional status. The Naples prognostic score (NPS) is an innovative biological marker capable of reflecting systemic inflammation and nutritional status. This research seeks to investigate the correlation of NPS with severe abdominal aortic calcification (SAAC).Methods: The research evaluated data obtained from the National Health and Nutrition Examination Survey (NHANES) conducted between 2013 and 2014. The variables were filtered utilizing the Least Absolute Shrinkage and Selection Operator (LASSO) regression. Weighted logistic regression models were employed to examine the association of NPS with SAAC. The predictive value of NPS for the risk of SAAC was assessed utilizing the receiver operating characteristic (ROC) curve. A subgroup analysis was conducted to assess the strength and reliability of the research findings.Results: The research encompassed 2,854 participants, among whom 303 (11.87%) exhibited SAAC. The outcomes of multivariate weighted logistic regression revealed that participants with a NPS of 3–4 points was positively correlated with SAAC in comparison to the control group [odds ratio (OR) = 2.07, 95% confidence interval (95%CI): 1.17–3.67]. The area under the curve (AUC) for predicting the risk of SAAC using NPS was 0.635. The subgroup analysis results indicated that there was no significant difference noted in the association of NPS with SAAC across various population subgroups.Conclusion: A positive association of NPS with SAAC has been observed in this research. This study offers valuable insights into the prevention and diagnosis of SAAC. Future longitudinal studies are warranted to confirm causative relationships and assess the role of NPS in clinical decision-making for SAAC.


  • A Systematic Review and Meta-Analysis of Efficacy and Safety of Cilostazol Prescription in Patients With Femoropopliteal Peripheral Artery Disease After Endovascular Therapy

    by Qiang Tan, Zhilong Chen, Huaping Wu, Haifei Wang, Jingquan Chen, Kun Lai, Fuzhao Zhang, Tengyao Kang, Jianghua Zheng

    Purpose: The purpose of this study is to assess the efficacy and safety of cilostazol prescription in patients with femoropopliteal peripheral artery disease (PAD) after endovascular therapy (EVT). Materials and methods: We conducted a systematic review and meta-analysis of all studies reporting the outcomes of cilostazol after femoropopliteal EVT of PAD up to September 2022. Clinical outcomes of interest included primary patency, in-stent restenosis (ISR), vessel re-occlusion, freedom from target lesion revascularization (TLR), repeat revascularization, all-cause mortality, amputation, major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs), and bleeding complication. Results: A total of 4 randomized controlled trials (RCTs) and 8 observational studies containing a total of 4898 patients met the inclusion criteria and were included in this systematic review and meta-analysis. We found that the use of cilostazol was associated with higher primary patency after femoropopliteal artery EVT (odds ratio [OR]=1.67, 95% confidence interval [CI]=1.50-1.87, p2 =33.2%), a lower risk of ISR (OR=0.43, 95% CI=0.29-0.63, p2 =37.6%), repeat revascularization (OR=0.43, 95% CI=0.24-0.76, p2 =27.4%), and vessel re-occlusion (OR=0.59, 95% CI=0.38-0.93, p2 =0%). There was an increase in freedom from TLR rate (OR=2.19, 95% CI=1.58-3.05, p2 =0%), as well as a reduction in the occurrence of MALEs (OR=0.50, 95% CI=0.29-0.85, p2 =0%). However, there was no significant difference in amputation, MACEs, all-cause mortality, and major bleeding complications. Subgroup analysis showed that cilostazol treatment in patients with femoropopliteal drug-eluting stents (DES) implantation remained associated with higher primary patency and a lower risk of ISR. Conclusions: After EVT of femoropopliteal artery lesions, additional oral cilostazol enhances primary patency, reduces the occurrences of ISR and vessel re-occlusion, diminishes the risks associated with MALEs, lowers the need for repeat revascularization, and increases freedom from TLR rates. However, it does not impact amputation, MACEs, all-cause mortality, or major bleeding complications. These findings suggest cilostazol as a potentially safe and effective adjunct therapy in patients with femoropopliteal PAD after EVT. Clinical Impact: After undergoing endovascular therapy (EVT) for femoropopliteal artery lesions, the addition of cilostazol to antiplatelet therapy can significantly improve primary patency, reducing the incidence of in-stent restenosis, repeat revascularization, vessel re-occlusion, and major adverse limb events while increasing freedom from target lesion revascularization rate. The simultaneous use of drug-eluting stents in the femoropopliteal artery lesions, combined with cilostazol, potentially results in a synergistic anti-stenotic effect. This therapeutic approach does not appear to be associated with an increased risk of major bleeding events or all-cause mortality. These findings provide additional evidence supporting the treatment of anti-stenosis in patients with femoropopliteal artery lesions after EVT.


  • Open Access

    Identification of multiomics map and key biomarkers in uveal melanoma with chromosome 3 loss

    by Xi Yong, Tengyao Kang, Tingting Li, Sixuan Li, Xuerui Hu, Xiang Yan, Fuzhao Zhang, Jianghua Zheng, Qin Yang

    Purpose: Chromosome 3 loss is an independent risk factor for uveal melanoma (UM), but its exact molecular mechanisms remain unclear. This study was designed to investigate the relationship between chromosome 3 loss and molecular alterations at multiple levels to construct a prognostic model. Methods: Forty-four UM cases with chromosome 3 loss (chr3 del group) and 36 UM cases without copy number variation on chromosome 3 (chr3 wt group) were collected from the Cancer Genome Atlas (TCGA). The TCGA dataset was subjected to a univariate Cox regression analysis to identify different expressed genes, and a subsequent random forest algorithm analysis revealed significant changes in different expressed genes, which were used to develop key biomarkers for UM. Following that, the immune cell infiltration analysis and drug sensitivity analyses were carried out. The UM cell line was then utilized to investigate the potential functions of the key biomarker via cell apoptosis, proliferation, cycle assays, WB, and RT-qPCR. Results: By analyzing the 80 cases data in TCGA, the authors unveiled molecular changes relevant to loss of chromosome 3 in UM as well as their poor survival. In addition, machine learning analysis identified three hub genes (GRIN2A, ACAN, and MMP9) as potential therapeutic targets. The differentially enriched pathways between the two groups were mainly about immune-system activity, and hub genes expression was also highly correlated with immune infiltration levels. Conclusion: Chromosome 3 loss has considerable clinical significance for UM, and GRIN2A may be useful in diagnosing, treating, and prognosticating the condition.

    • 1 January 2019
      • Vol. 23  (1) , 87-95

    MiR-32-5p regulates the proliferation and metastasis of cervical cancer cells by targeting HOXB8

    by Y-J Liu, H-G Zhou, L-H Chen, D-C Qu, C-J Wang, Z-Y Xia, J-H Zheng

    OBJECTIVE: To investigate the effects of miR-32-5p on the biological behaviors of cervical cancer (CCa), the relevant mechanism was studied in CCa cell lines (HeLa) in vitro. PATIENTS AND METHODS: The expression level of miR-32-5p was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). TargetScan, miRDB, microRNA databases and Luciferase method were conducted to predict and validate the target gene of miR-32-5p; the effects of miR-32-5p on cell proliferation, clone formation, invasion and migration capacity were analyzed in vitro study. RESULTS: We found miR-32-5p to be significantly inhibited in CCa tissues and cells. Bioinformatics approach together with Luciferase method screened Homeobox B8 (HOXB8) as a downstream regulatory target of miR-32-5p. Besides, HOXB8 was incredibly high expression in CCa tissues and cells. After transfection in He La cells by miR-32-5p mimics, HOXB8 expression was indicated to be negatively correlated with miR-32-5p both in qRT-PCR and Western blot (WB) assays. The subsequent experiments showed that decreased expression of HOXB8 resulting from up-regulation of miR-32-5p could weaken the cell proliferation, clone formation, invasion and migration ability of HeLa cells. CONCLUSIONS: MiR-32-5p could inhibit the cellular malignant behavior through regulating the expression of HOXB8 in HeLa cells. We provide a new clue for the study of molecular mechanisms of CCa. MiR-32-5p/HOXB8 axis might serve as potential target for the clinical diagnosis and treatment of CCa.